Ticagrelor Improves Endothelial Function by Decreasing Circulating Epidermal Growth Factor (EGF)

Area of Science:

• Cardiology
• Vascular Biology
• Pharmacology

Background:

• Ticagrelor and clopidogrel are P2Y12 inhibitors used in percutaneous coronary intervention (PCI).
• Previous studies indicated ticagrelor improves endothelial function in patients with Stable Coronary Artery Disease (SCAD) and Chronic Obstructive Pulmonary Disease (COPD) undergoing PCI.
• Endothelial dysfunction is a key factor in cardiovascular and pulmonary diseases.

Purpose of the Study:

• To investigate the effect of ticagrelor versus clopidogrel on circulating epidermal growth factor (EGF) levels and endothelial nitric oxide synthase (eNOS) activation.
• To explore the relationship between EGF, platelet reactivity, and endothelial function.
• To elucidate the mechanism by which ticagrelor influences endothelial function in SCAD-COPD patients.

Main Methods:

• A clinical trial comparing ticagrelor and clopidogrel treatment in SCAD-COPD patients undergoing PCI.
• Measurement of circulating EGF levels and platelet reactivity after one month of treatment.
• In vitro studies using human umbilical vein endothelial cells (HUVEC) incubated with patient sera.
• Assessment of p-eNOS levels and eNOS activity in HUVEC.

Main Results:

• Ticagrelor treatment, unlike clopidogrel, significantly decreased circulating EGF levels.
• Decreased EGF levels correlated with on-treatment platelet reactivity.
• Ticagrelor treatment increased p-eNOS levels in HUVEC, suggesting eNOS activation.
• In vitro, EGF was found to decrease eNOS activity in a dose-dependent manner.

Conclusions:

• Ticagrelor improves endothelial function by reducing circulating EGF levels.
• This reduction in EGF leads to the activation of eNOS in the vascular endothelium.
• The findings provide a mechanistic link between ticagrelor's antiplatelet effect and improved endothelial function in SCAD-COPD patients.